T1	Outcomes 185 246	efficacy, tolerability and first-dose blood-pressure response
T2	Outcomes 836 844	Efficacy
T3	Outcomes 849 857	assessed
T4	Outcomes 866 1069	six-minute walking test, the New York Heart Association (NYHA) class, a functional lifescale (FLS) questionnaire and the cardiothoracic ratio (CTR)-at study entry and at the end of the maintenance phase.
T5	Outcomes 1070 1084	Blood pressure
T6	Outcomes 1336 1395	distance walked during the six-minute walking test improved
T7	Outcomes 1464 1490	statistically significant.
T8	Outcomes 1505 1524	significant changes
T9	Outcomes 1532 1543	FLS or CTR.
T10	Outcomes 1624 1660	statistically significant difference
T11	Outcomes 1759 1770	hypotension
T12	Outcomes 1966 2001	first-dose blood-pressure response.
